MedTrace Logo

Possibilities of Phytomedicine in Monotherapy of Benign Breast Diseases

NCT05717894 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2023-02-08

No results posted yet for this study

Summary

The aim of this study is to evaluate the effectiveness of the use of the drug, containing Vitex agnus castus extract (VAC), in patients with fibrocystic breast disease . One hundred fifty women over 40 years old were randomized into patient (n=78) and control (n=72) groups. The groups were similar regarding age, nulliparity, menopause and abortion status, family history of breast cancer, alcohol consumption, and smoking. The patient group received two pills containing 200mg of VAC daily for six months, and all participants were evaluated by using a Visual Analogue Scale and ultrasound examination at baseline, 12th and 24th weeks.

Conditions

  • Fibrocystic Breast Disease

Interventions

DRUG

Vitex Agnus Castus Extract

The patient group received two pills containing 200mg of VAC daily for six months

Sponsors & Collaborators

  • Nazgul Omarbayeva

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-11
Primary Completion
2022-05-15
Completion
2022-06-10

Countries

  • Kazakhstan

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05717894 on ClinicalTrials.gov